Related Experiment Videos
Glycoprotein IIb/IIIa platelet receptor inhibitors: a new dimension in cardiology
1Cardiac Department, National University Hospital, Singapore.
Insights
Platelet glycoprotein (GP) IIb/IIIa receptor antagonists are novel antiplatelet agents targeting thrombus formation. These drugs show promise in reducing ischemic complications in acute coronary syndromes and angioplasty.
Area of Science:
- Cardiovascular Medicine
- Hematology
- Pharmacology
Background:
- Platelets are crucial in atherosclerosis and thrombotic events.
- Platelet aggregation, mediated by the GP IIb/IIIa receptor, drives thrombus formation.
- GP IIb/IIIa receptor antagonists represent a new class of antiplatelet therapy.
Purpose of the Study:
- To review the biology of the GP IIb/IIIa receptor.
- To discuss the different classes of GP IIb/IIIa receptor antagonists.
- To summarize clinical trial results and their impact on practice.
Main Methods:
- Literature review of GP IIb/IIIa receptor biology.
- Analysis of clinical trial data for GP IIb/IIIa antagonists.
- Synthesis of current knowledge on antiplatelet therapy.
Main Results:
- The GP IIb/IIIa receptor is a key target for antiplatelet drugs.
- Various GP IIb/IIIa receptor antagonists have been developed and tested.
- These agents demonstrate potential in managing thrombotic complications.
Conclusions:
- GP IIb/IIIa receptor antagonists are significant in treating cardiovascular diseases.
- Understanding receptor biology informs therapeutic strategies.
- Clinical application is evolving based on trial outcomes.
Abstract:
Platelets play a key role in the pathogenesis of atherosclerosis, acute coronary syndromes and ischaemic complications following percutaneous coronary intervention. More recently, the platelet glycoprotein (GP) IIb/IIIa receptor has been identified as the pivotal mediator of platelet aggregation, leading to thrombus formation. This has led to the emergence of a novel class of potent antiplatelet agent, the GP IIb/IIIa receptor antagonists. These agents show great promise in reducing ischaemic complications of coronary angioplasty and acute coronary syndromes. This review summarizes the current state of knowledge of the biology of GP IIb/IIIa receptor, the different classes of GP IIb/IIIa receptor antagonists, the results of the various trials, and their impact on current clinical practice.